Remove Generic Drugs Remove Marketing Remove Packaging
article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

Japan is currently the fourth largest market in the world. Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 Other contributing factors include the decreasing number of post-market studies and difficulties in primary research and manufacturing.

Marketing 173
article thumbnail

FDA Sort-of Commits to Meet with Generic Drug Manufacturers that Have Received Warning Letters

FDA Law Blog

Food and Drug Administration – labeled an “Official Action Indicated” classification – is generally devastating for the facility, not least because it can stall FDA approval of applications to market drugs manufactured at the facility.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

Japan is currently the fourth largest market in the world. Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 Other contributing factors include the decreasing number of post-market studies and difficulties in primary research and manufacturing.

Marketing 130
article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

The goal of getting a drug to market as fast as possible so they can recoup drug development costs has the potential for mistakes that could cost lives. Coupled with all this is the continued outsourcing of raw materials and other steps in drug development. Patients should be scared.

article thumbnail

Our abysmal health care system

World of DTC Marketing

Once limited to a few new treatments, it’s now being applied widely, even to generic drugs and established regimens.?The Andrew Witty, its CEO, had a 2021 pay package worth $18.4 In many cases, one drug may drive your decision — typically a brand name or a high-tier generic that only a few plans cover effectively.

Doctor 263
article thumbnail

Five Trends in Contract Drug Manufacturing Organisations

Pharmaceutical Technology

For pharma and biotech companies, there are many advantages to partnering with a Contract Development and Manufacturing Organisations (CDMO): they can access more specialized knowledge, state-of-the-art equipment, and qualified staff, as well as reduce their total cost of ownership, all while maintaining speed to market.

article thumbnail

In the News: November Regulatory and Development Updates

Camargo

Evergreening Orphan Drugs May Be Over. The Orphan Drug Act of 1983 provides market exclusivity for drugs intended to treat conditions affecting fewer than 200,000 patients in the US. Practically, this act (which still must be considered by the Senate) will mainly apply to orphan drugs granted exclusivity prior to 2017.